Key result
Icariin improves cardiac function and reduces fibrosis in rat MI models by suppressing TGF-β1/Smad signaling.
Why the study?
The study was conducted to assess the effects of icariin on myocardial fibrosis and ventricular remodeling in rats subjected to myocardial infarction.
Does icariin improve cardiac function and prevent remodeling in a rat model of myocardial infarction?
Does icariin improve cardiac function and prevent remodeling in a rat model of myocardial infarction?
Icariin demonstrates cardioprotective effects in a rat model of post-MI remodeling by improving cardiac function and reducing fibrosis via the TGF-β1/Smad pathway.
Answers are grounded in this paper and cite their sources.
Should not change post-MI practice; hypothesis-generating for icariin in human heart failure trials.
BACKGROUND: Postinfarction cardiac remodeling presents a compensatory mechanism aimed at mitigating congestive heart failure. It is distinguished by progressive dilatation and hypertrophy of the ventricular chambers, fibrotic alterations, and prolonged apoptosis of cardiomyocytes. The primary objective of this study was to assess the effects of icariin on myocardial fibrosis and ventricular remodeling in rats subjected to myocardial infarction (MI). METHODS: Male Sprague‒Dawley (SD) rats were subjected to randomization and subsequently divided into distinct groups: the control group, the sham group (undergoing sham operation), the MI group (experiencing ligation of the left anterior descending artery), and the icariin group. Within the icariin group, rats were further categorized into three different dose groups based on the administered icariin dosage: the MI30 group (30 mg/kg/day), the MI60 group (60 mg/kg/day), and the MI120 group (120 mg/kg/day). Cardiac function evaluation was carried out using echocardiography. Histological examinations, including hematoxylin and eosin (HE) staining, Masson staining, and immunohistochemistry studies, were conducted 90 days after the occurrence of MI. Additionally, Western blotting was employed to assess TGF-β1, p-Smad2, and p-Smad3 levels. RESULTS: The administration of icariin revealed a noteworthy enhancement in cardiac function among rats afflicted with left anterior descending coronary artery (LAD) ligation. In comparison to the icariin groups, the MI group exhibited reduced EF and FS, along with elevated LVEDD and LVESD. Furthermore, the cardiac fibrosis levels in the MI group rats exhibited a considerable increase compared to those in the icariin group. Notably, the levels of Collagen I, Collagen III, MMP2, and MMP9 were significantly higher in the MI group than in the icariin group, with evident distinctions. Moreover, the expression levels of TGF-β, IL-13, p-Smad2, and p-Smad3 were notably upregulated in the MI group compared to the icariin group. CONCLUSIONS: In an experimental rat model of MI, the administration of icariin resulted in the amelioration of both cardiac function and remodeling processes, operating through the intricate TGF-β1/Smad signaling pathway.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2023) studied Myocardial infarction. Icariin vs. Myocardial infarction without icariin treatment was evaluated on Cardiac function (Ejection Fraction and Fractional Shortening) and myocardial fibrosis (p=<0.05). In a rat model of myocardial infarction, administration of icariin significantly improved cardiac function and reduced myocardial fibrosis by suppressing the TGF-β1/Smad signaling pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: